HomeGreater Than Icon
Hester Biosciences LtdGreater Than Icon
Hester Biosciences Ltd Financials
Company Logo

Hester Biosciences Ltd Financial Statement

Hester Biosciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue74.85
Operating Expense58.77
Net Profit9.34
Net Profit Margin12.48
Earning Per Share10.97
EBIDTA16.00
Effective Tax Rate19.09

Hester Biosciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual285.16
Operating Expenses Annual237.81
Operating Profit Annual51.60
Interest Annual5.09
Depreciation9.78
Net Profit Annual27.16
Tax Annual9.57

Hester Biosciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning4.30
Cash Flow from Operations42.81
Cash Flow from Investing-20.63
Cash Flow from Financing-24.07
Cash Flow at the End2.41

Hester Biosciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)18.10
PBIT Margin (%)14.67
PBT Margin (%)11.79
Net PROFIT Margin (%)9.52
Return On Networth / Equity (%)8.98
Return On Networth /Employed (%)8.51
Return On Assets (%)5.52
Total Debt / Equity (X)0.49
Asset Turnover Ratio (%)0.58

Hester Biosciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual106.75
Total Current Assets Annual204.41
Non Current Assets Annual345.13
Total Shareholders Funds Annual312.71
Total Assets Annual549.55

Hester Biosciences Ltd Earning Calls

EPS (INR)

Expected

9.64

Reported

9.86

Surprise

2.28%

Jun 2024

EPS beaten by 2.28%

Mar 2024

EPS beaten by 18.12%

Dec 2023

EPS beaten by 29.21%

Get Your FAQs Right

As of Nov 5, 2024, Hester Biosciences Ltd has a market capitalization of 1,181.82 Cr. Value Research classifies it as a Small-Cap company.
Yes, Hester Biosciences Ltd is debt-free with a debt-to-equity ratio of 0.43.
In FY 2023 , Hester Biosciences Ltd recorded a total revenue of approximately 285.16 Cr marking a significant milestone in the company's financial performance.
Hester Biosciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.3% and 0.1% annually, respectively..
Hester Biosciences Ltd's current PE ratio is 43.51.
Hester Biosciences Ltd's ROCE averaged 11.0% from the FY ending March 2022 to 2024, with a median of 10.5%. It peaked at 14.3% in March 2022, reflecting strong capital efficiency over the period..
Hester Biosciences Ltd's latest EBIT is Rs. 41.82 Cr, surpassing the average EBIT of Rs. 49.32 Cr over the 5 years..